Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies

Author(s): Shin-ichi Satoh, Ichiro Ikegaki, Koh Kawasaki, Toshio Asano, Masato Shibuya

Journal Name: Current Vascular Pharmacology

Volume 12 , Issue 5 , 2014

Become EABM
Become Reviewer
Call for Editor


There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.

Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [758 - 765]
Pages: 8
DOI: 10.2174/1570161112666140613115813
Price: $65

Article Metrics

PDF: 58